Accucaps establishes SPC for high potency compounds
Accucaps said that the increase in growth of liquid filled soft gel formulated compounds is due to the increasing need to formulate high potency molecules that could not
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
Immunovaccine’s DepoVax platform is a lipid depot-based vaccine delivery technology. The primary cell-derived biologic, IRX-2, designed to restore the immune system, seeks to overcome cancer-induced immune suppression and